[EN] MTA-COOPERATIVE PRMT5 INHIBITORS<br/>[FR] INHIBITEURS DE PRMT5 COOPÉRATIF À BASE DE MTA
申请人:MIRATI THERAPEUTICS INC
公开号:WO2022192745A1
公开(公告)日:2022-09-15
Disclosed are compounds of Formula IIA, IIA-1, IIB, IIB-1, IIC and IIC-1: and pharmaceutical compositions and methods of use thereof These compounds inhibit Protein Arginine M-Methyl Transferase 5 (PRMT5) activity and are useful in methods and pharmaceutical compositions for treating cancer.
作者:Machín Rivera, Roger、Ferrin, Zack R.、Lindsay, Vincent N. G.
DOI:10.1021/acs.orglett.4c01528
日期:——
approach to medicinally relevant pyrroloindolones and related fused heterocycles is reported via the diastereoselective N-addition of unprotected indoles to readily accessible cyclopropanone equivalents. The resulting stable hemiaminals are shown to smoothly rearrange to pyrroloindolones in mild conditions using Fe(III) catalysis in the presence of inexpensive ammonium persulfate as a stoichiometric oxidant
A facile synthetic route has been developed for the preparation of pyrrolizinone derivatives employing N-allyl imides as starting materials. The nucleophilic addition of a vinyl Grignard reagent/RCM/elimination sequence afforded pyrrolizinones in good yields and has been applied for the preparation of naturally occurring quinolactacide and marinamide.